New cocktail therapy shows promise for tough stomach cancers
NCT ID NCT05177068
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 27 times
Summary
This study tests a combination of three drugs (fruquintinib, sintilimab, and SOX chemotherapy) in 42 people with advanced stomach cancer that has spread but might still be removable. The goal is to shrink the tumors enough to allow complete surgical removal. The main focus is on how many patients can have successful surgery with no cancer left behind.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Tumor Hospital
Zhengzhou, Henan, 450000, China
Conditions
Explore the condition pages connected to this study.